On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) met to evaluate seven peptide-related bulk drug substances for potential inclusion on the 503A Bulks List. For patients and providers following the compounded peptide updates, this meeting is a significant moment in an ongoing regulatory process. What Was Review...
